In the CROWN study, the median PFS (mPFS) of ALK-positive NSCLC patients treated with crizotinib was 9.3 months, whereas that of the Lorlatinib prolonged the PFS of patients (61–65). Here, ALK is linked to non-small cell lung carcinoma.